Trial Profile
A Phase 1 Placebo-controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of Single Escalating Oral Doses of PF-05190457 Under Fasted and Fed Conditions in Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2020
Price :
$35
*
At a glance
- Drugs PF 5190457 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; First in man; Pharmacokinetics
- Acronyms SAD
- Sponsors Pfizer
- 05 Nov 2020 Results (n=47)of pooled analysis from NCT01247896 and NCT02039349 evaluaitng population pharmacokinetic model for PF-5190457, published in the Clinical Pharmacokinetics
- 13 Sep 2016 Results assessing safety, pharmacokinetics and pharmacodynamics of SAD and MAD studies published in the British Journal of Clinical Pharmacology.
- 05 Jul 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.